| Vifor (International) AG - Flucelvax Tetra, Injektionssuspension | | 67482 | | 02 | | Flucelvax Tetra | | Injektionssuspension | | J07BB02 | | Influenza, Inactivated, Split Virus Or Surface Antigen | | 19.07.2024 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus Stamm A/Wisconsin/67/2022 (H1N1)-like: derived from A/Georgia/12/2022 CVR-167) 15 µg, haemagglutininum influenzae A (H3N2) (Virus Stamm A/Massachusetts/18/2022 (H3N2)-like: derived from A/Sydney/1304/2022) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Austria/1359417/2021-like: reassortant from B/Singapore/WUH4618/2021 (Victoria lineage)) 15 µg, haemagglutininum influenzae B (Virus Stamm B/Phuket/3073/2013-like: reassortant from B/Singapore/INFTT-16-0610/2016 (Yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, magnesii chloridum hexahydricum, natrii dihydrogenophosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.7 mg, kalium 0.1 mg, residui: polysorbatum 80, cetrimidum, propiolactonum. | | Packungsbestandteile | | Injection suspension | | | | | | | | Active Agent | Dose |
|---|
| Haemagglutininum Influenzae a (H1N1) (Virus Stamm A/wisconsin/67/2022 (H1N1)-Like: Derived from A/georgia/12/2022 Cvr-167) | 15µg / 0.5ml | | Haemagglutininum Influenzae a (H3N2) (Virus Stamm A/massachusetts/18/2022 (H3N2)-Like: Derived from A/sydney/1304/2022) | 15µg / 0.5ml | | Haemagglutininum Influenzae b (Virus Stamm B/austria/1359417/2021-Like: Reassortant from B/singapore/wuh4618/2021 (Victoria Lineage)) | 15µg / 0.5ml |
| | BAG: Active Agent | Dose |
|---|
| Influenza-haemagglutinin | 0.06 mg |
| | | | Inactive agents | Dose |
|---|
| Haemagglutininum Influenzae b (Virus Stamm B/phuket/3073/2013-Like: Reassortant from B/singapore/inftt-16-0610/2016 (Yamagata Lineage)) | 15µg / 0.5ml | | Potassium Chloride | | | Potassium Dihydrogenophosphate | | | Magnesium Chloride Hexahydrate | | | Sodium Chloride | | | Sodium Dihydrogenophosphate Dihydrate | |
| |
| |
|
